Tesamorelin
Tesamorelin Acetate
Tesamorelin is a synthetic form of growth hormone-releasing hormone (GHRH). It is FDA-approved for reducing excess abdominal fat in HIV patients with lipodystrophy. It has become of interest for its ability to reduce visceral adipose tissue.
Buy Tesamorelin at Peptide PalacePurity
99%+
Molecular Weight
5135.89 g/mol
Administration
Subcutaneous injection
Storage
Store at 2-8°C or below 25°C for up to 3 months
Mechanism of Action
Tesamorelin binds to GHRH receptors in the pituitary gland, stimulating the production and pulsatile release of growth hormone. The increased GH levels then promote lipolysis, particularly in visceral fat stores.
Sequence:
Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 Chemical Structure
Research Areas
- HIV-associated lipodystrophy
- Visceral fat reduction
- Metabolic syndrome
- NAFLD/NASH
- Body composition
Potential Benefits
- Reduced visceral fat
- Improved body composition
- Preserved natural GH pulsatility
- Potential liver benefits
- Improved metabolic markers
Research Dosing Guidelines
For research purposes only. Not for human consumption.
Typical Dose
2 mg
Frequency
Once daily
Duration
12-26 weeks in clinical trials
Administration
Subcutaneous injection
Inject at same time each day. Can be administered in morning or evening.
Reconstitution Calculator
U-100 Insulin Syringe
0.2 units
1000 mcg/ml
0.0020 ml
0.2 IU
1000
For research and educational purposes only. Always follow proper reconstitution and sterile handling protocols.
GHRH Analog Comparison: Tesamorelin vs CJC-1295 vs Sermorelin
All three peptides stimulate growth hormone release through the GHRH receptor, but their pharmacokinetics and clinical validation differ substantially.
GHRH Analog Comparison
| Factor | Tesamorelin | CJC-1295 (DAC) | Sermorelin |
|---|---|---|---|
| FDA approved? | Yes (HIV lipodystrophy) | No | Previously (withdrawn commercially) |
| Half-life | 26 minutes | ~8 days (with DAC) | ~12 minutes |
| Dosing | 2 mg daily | 1-2 mg weekly | 200-500 mcg nightly |
| GH pattern | Natural pulsatile | Sustained elevation | Natural pulsatile |
| Primary indication | Visceral fat reduction | General GH optimization | Anti-aging, sleep |
| Clinical evidence | Strongest (Phase III trials) | Limited (Phase II) | Moderate |
Tesamorelin has the strongest clinical evidence base of any GHRH analog, with large-scale trials demonstrating efficacy for visceral fat reduction. However, its daily dosing requirement and higher cost make CJC-1295 and Sermorelin popular alternatives in research settings.
Potential Side Effects
- Injection site reactions
- Joint pain
- Peripheral edema
- Muscle pain
- Paresthesia
Storage Requirements
Store at 2-8°C or below 25°C for up to 3 months.
Research References
- [1]Tesamorelin and Visceral Adipose Tissue (2010)Strong Evidence Population: HIV-positive adults with abdominal lipohypertrophy (n=412)
Tesamorelin reduced trunk fat by 15% and visceral adipose tissue significantly in HIV-positive patients with lipodystrophy.
Limitations: Population-specific (HIV lipodystrophy); effects may differ in general obesity
- [2]Reduction in Visceral Adiposity and Improved Metabolic Profile (2012)Strong Evidence Population: HIV-infected adults with lipodystrophy (n=806)
26-week tesamorelin treatment significantly reduced VAT and improved triglyceride levels without adverse glucose effects.
Limitations: Treatment effects reversed upon discontinuation; requires ongoing administration
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin is a synthetic form of growth hormone-releasing hormone (GHRH) that is FDA-approved for reducing excess abdominal fat in HIV patients with lipodystrophy. It preserves the natural pulsatile pattern of growth hormone release, making it distinct from direct GH administration.
What are the potential research benefits of Tesamorelin?
Research suggests Tesamorelin may reduce visceral fat, improve body composition, and enhance metabolic markers. By stimulating pulsatile growth hormone release through GHRH receptors, it specifically targets visceral adipose tissue for lipolysis.
How is Tesamorelin typically dosed in research?
Tesamorelin is typically administered at 2 mg once daily via subcutaneous injection at a consistent time each day. Clinical trials have employed 12-26 week protocols, with both morning and evening administration showing efficacy.
What are the side effects of Tesamorelin?
Side effects of Tesamorelin may include injection site reactions, joint pain, peripheral edema, muscle pain, and paresthesia. These effects are generally manageable and consistent with increased growth hormone activity.
How should Tesamorelin be stored?
Tesamorelin should be stored at 2-8°C, or it may be kept below 25°C for up to three months. Following these storage guidelines ensures the peptide maintains its potency and stability.
Ready to Purchase Tesamorelin?
Get the highest quality Tesamorelin from our recommended vendor with 99%+ purity guaranteed.
Buy at Peptide PalaceRelated Topics
Peptide Hormones and Their Functions
Peptide hormones are hydrophilic signaling molecules that bind cell surface receptors, triggering intracellular cascades via second messengers like cAMP and calcium.
Therapeutic Applications of Peptides
Therapeutic peptides occupy the pharmacological space between small molecules and biologics, offering high selectivity for protein-protein interactions with lower immunogenicity.
Safety & Reference
Related Peptides
CJC-1295
CJC-1295 (with or without DAC)
CJC-1295 is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH), originally developed by ConjuChem Biotechnologies. It stimulates the pituitary gland to release growth hormone in a dose-dependent manner. It comes in two forms: with DAC (Drug Affinity Complex), which uses a maleimidopropionic acid linker to bind the peptide to serum albumin and extend its half-life to roughly 8 days, and without DAC (also called Mod GRF 1-29), which has a half-life of about 30 minutes and produces sharper, more natural GH pulses.
Learn MoreSemaglutide
Semaglutide Acetate
Semaglutide is a GLP-1 receptor agonist that mimics the effects of the naturally occurring hormone GLP-1. It has gained significant attention for its powerful effects on appetite regulation and blood sugar control, leading to substantial weight loss in research subjects.
Learn MoreAOD-9604
Advanced Obesity Drug 9604
AOD-9604 is a modified fragment of human growth hormone (HGH) specifically designed to have the fat-reducing effects of HGH without the negative side effects on blood sugar or growth. It corresponds to the C-terminal portion of HGH.
Learn More